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Abstract
Background: The efficacy of exercise therapy for ankylosing spondylitis (AS) is well-documented, but dearth of
information is for non-radiographic axial spondyloarthritis (nr-axSpA).
Biomarkers like serum calprotectin, interleukins IL-6, IL-17 and tumour necrosis factor (TNF)-α may reflect the disease
activity of axial spondyloarthritis (axSpA). In this study, we investigated clinical and laboratory parameters of both axSpA
subgroups in response to intensive physical exercise.
Methods: Altogether, 46 patients with axSpA, characterised according to the Assessment of SpondyloArthritis
International Society criteria as having nr-axSpA or AS underwent 6-month exercise programme. Clinical outcomes of
disease activity, Bath AS Disease Activity Index (BASDAI), AS Disease Activity Index (ASDAS-CRP), mobility, Bath AS
Metrology Index (BASMI) and function, Bath AS Functional Index (BASFI) were evaluated at baseline and at the end of
the exercise programme. Serum IL-6 and IL-17, TNF-α and calprotectin were measured via ELISA. The clinical and
laboratory data of 29 control axSpA patients were used for the evaluation of the results.
Results: In all axSpA patients, the ASDAS-CRP (2.10 ± 0.12 to 1.84 ± 0.11, p <0.01) and BASMI (1.28 ± 0.14 to 0.66 ± 0.84,
p <0.0001) improved after 6 months of exercise therapy. There was a significant improvement in the ASDAS-CRP in the
nr-axSpA subgroup (2.01 ± 0.19 to 1.73 ± 0.16, p <0.05) and in the BASMI in both, the nr-axSpA and the AS subgroups
(1.09 ± 0.12 to 0.47 ± 0.08, p <0.0001 and 1.43 ± 0.24 to 0.82 ± 0.23, p <0.0001, respectively). Both, ASDAS-CRP and
BASDAI, were significantly improved in the exercise axSpA group compared to the control axSpA group (mean -0.26 vs.
-0.13 and -0.49 vs. 0.12, respectively, all p <0.05). Only calprotectin was significantly reduced after the exercise
programme in nr-axSpA and AS patients (from 2379.0 ± 243.20 to 1779.0 ± 138.30 μg/mL and from 2430.0 ± 269.70 to
1816.0 ± 148.20 μg/mL, respectively, all p <0.01). The change in calprotectin was more profound in the axSpA
intervention group (mean -604.56) than in the control axSpA (mean -149.28, p <0.05).
Conclusion: This study demonstrated similar efficacy for an intensive exercise programme in both nr-axSpA and AS
patients. A significant decrease in serum calprotectin levels in both subgroups of axSpA patients after the exercise
programme reflected an improvement in the disease activity and spinal mobility.
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Background
Axial spondyloarthritis (axSpA) is thought to consist of
two subtypes of one disease that share similar features,
such as inflammatory back pain, peripheral arthritis,
enthesitis, dactylitis, various extraarticular manifestations
and a genetic background, which is evident in a common
family history and HLA B27 positivity. The hallmarks of
axSpA in particular are inflammation in the sacroiliac
joints (SIJ) and in the tendons of the axial skeleton [1, 2].
The radiographic axSpA variant ankylosing spondylitis
(AS) has been well-characterised by the modified New
York criteria, which include evidence of typical bone
changes on conventional radiographs of the SIJ [1]. The
non-radiographic subgroup, nr-axSpA, on the other
hand, can manifest as a spectrum of spondyloarthritic
signs together with either human leukocyte antigen
(HLA)-B27 positivity or inflammation of the SIJ, which
can be detected by magnetic resonance imaging (MRI)
but not by conventional radiography [2]. Although dis-
tinct differences, such as female-to-male ratio, impaired
function, mobility and levels of C-reactive protein (CRP)
distinguish AS from nr-axSpA, an analogous disease
course and clinical activity are common to both sub-
groups, and nr-axSpA is considered to be an earlier
stage of AS [3]. Similarly, an identical management
approach to both subgroups of axSpA is proposed in
the guidelines of the Assessment of SpondyloArthritis
International Society (ASAS) [4].
Reduced disease activity and improved quality of life are
the main treatment goals for patients with axSpA.
Pharmacological agents, including non-steroidal anti-
inflammatory drugs (NSAIDs) and tumour necrosis factor
(TNF)-α inhibitors (TNFi), are efficacious in a majority of
patients even though the effect of current treatment on
structural progression remains unclear [5]. A combination
of both pharmacological and non-pharmacological inter-
ventions such as physiotherapy and education, however,
appears to be more effective in controlling the disease ac-
tivity [6, 7] and periodic exercise ameliorates the effect of
long-term AS on disability and deformity [8]. Current rec-
ommendations for AS exercise therapy focus not only on
the modification of AS musculoskeletal sequelae but also
on the secondary consequences of AS such as balance
disturbances and cardiorespiratory abnormalities [7].
However, the efficacy of exercise therapy per se in patients
with nr-axSpA has not yet been elucidated.
Disease activity and severity of axSpA are well-
documented in a number of established indices, but only
the AS Disease Activity Score (ASDAS) reflects inflam-
matory activity with entry values of CRP and patient-
reported valuations [9]. Although increased CRP alone is
not a specific condition of high AS disease activity and
has only been found to be common in 40–50% of pa-
tients [10], they serve as a biomarker for the evaluation
of inflammation in daily practice. Several other bio-
markers, cytokines in particular, are purported to have a
connection to disease activity and severity. Interleukins
such as IL-6 and IL-17 and TNF-α are presumed to play
an important role in axSpA pathogenesis due to the
initiation and maintenance of inflammation [11–13]. In
addition to the overproduction of IL-6 and TNF-α in SIJ
tissues [11, 12], patients with greater disease activity
were also found to have elevated circulating levels of
IL-6, IL-17 and TNF-α [14, 15]. Similarly, calprotectin
(S100A8/S100A9 heterodimer) is mainly produced by
monocytes that infiltrate the inflamed synovium dur-
ing spondyloarthritis [16], and elevated systemic levels
reflect global autoimmune inflammation [17].
In this study, we carried out a 6-month exercise and
education programme for patients who were suffering
from both nr-axSpA and AS. We investigated the impact
of intensive physical training on disease activity in the
whole group and, in particular, on differences between
the two defined subgroups. Variations in biomarker
serum levels as affected by exercise were also evaluated.
Methods
Patients
AxSpA with exercise programme
A total of 46 patients with axSpA who were attending
the Institute of Rheumatology in Prague were included
in this study. All of the patients fulfilled the ASAS classi-
fication criteria for axSpA [2] and according to these cri-
teria were characterised as having nr-axSpA (n = 23) or
AS (n = 23). Patients in the nr-axSpA group had clinical
signs and symptoms of SpA and were either positive for
the HLA-B27 antigen and/or had inflammatory changes
in the SIJ on MRI (73.9%) but no changes on radiog-
raphy. All of the AS patients fulfilled the modified
New York criteria for the diagnosis of AS, including the
radiographic criterion [1]. Eight patients with AS with a
longer disease duration (14.76 ± 2.17 and 9.50 ± 2.98 years
since the first symptoms and diagnosis, respectively) had
spinal involvement (25%), and fifteen patients with AS with
shorter disease duration (11.93 ± 1.80 and 5.30 ± 1.26 years
since the first symptoms and diagnosis, respectively) only
had SIJ involvement. All of the patients with axSpA
were fully or partially employed, mostly (95.7% of
both nr-axSpA and AS) as “white-collar” workers [18].
The inclusion criteria for the study were stable disease
and treatment for at least 6 months prior to baseline. Dur-
ing the entire study, transient changes in the dose of
NSAIDs were allowed. Patients must not have received
oral or intraarticular glucocorticoids during the study.
Control group - patients with axSpA with no intervention
The control group consisted of 29 age-matched and sex-
matched patients with axSpA. Out of the control group,
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15 subjects had nr-axSpA. All of the patients from the
control group were selected retrospectively from the
axSpA cohort in Prague, and the following parameters
were required: dates of two medical examinations
(marked as visits 1 and 2) that occurred concurrently
with the ongoing study, stable disease activity and treat-
ment for at least 6 weeks prior to visit 1, and no changes
in pharmacological or other therapy between visits 1 and
2. In particular, subjects from the control group must
not have undergone physical therapy, physical exercise
or spa treatment for at least 6 weeks prior to baseline
and between the two consecutive visits. Daily home
exercise without any supervision and mobilisation
techniques or massage was allowed. All of the control
patients with axSpA were fully or partially employed,
and the percentages of white-collar workers [18] were
93.4% for nr-axSpA and 85.7% for AS (not significantly
different from groups with exercise).
Intervention
This was a 6-month single-centre study that started in
September 2013. All of the subjects from the interven-
tion group underwent outpatient group physiotherapy
for 60 minutes twice a week and a daily home-based ex-
ercise programme. The absence of more than two con-
secutive sessions of outpatient physiotherapy excluded
patients from further participation in the study. The su-
pervised exercise unit was made up of three sections:
warm-up at the beginning, the main part and cool-down
at the end. During the warm-up, cardiorespiratory fit-
ness methods were used. These methods focused on
concentration, core strengthening and spinal traction.
The following exercises were employed: spinal (rotatory)
exercises developed by Cumpelik [19], an educational
back school method [20] and McKenzie therapy [21],
posture correction according to the Brügger concept
[22], elements derived from pilates [23] and muscle
stretching. The major part was dedicated to the practice of
correct activation of deep core stabilisation and the precise
involvement of muscles in motion and balance training,
particularly using BOSU balls, which are an established
method for the encouragement of abdominal muscle
activity [24] as a tool for stretching, lumbar strengthening
and hip-joint mobility [25]. The final part (cool-down) con-
sisted of techniques of relaxation, breathing exercises and
elements of yoga. Additionally, physiotherapy education
for homework - practical training in postural correction
exercises and motivation to change the daily routine was
used at the end of the exercise unit.
Outcome measurements
Clinical
The clinical examination of signs of axSpA, including
extraarticular manifestation, was carried out in all
patients before and a few days (maximum 7 days) after
the exercise programme termination. The measurement
tools for disease activity and severity evaluation were the
Bath AS Disease Activity Index (BASDAI) [26], Bath AS
Functional Index (BASFI) [27], the 10 point Bath AS
Metrology Index (BASMI) [28] and the AS Disease
Activity Index (ASDAS)-CRP [9]. BASMI was rated by
the same physiotherapist at the beginning and at the end
of the exercise programme. In the control axSpA group,
in which no intervention was performed, the disease
activity was assessed using the BASDAI, BASFI and
ASDAS-CRP in two consecutive visits after 6 months.
The BASMI, however, was not available for this analysis.
Biomarkers
In the intervention group, serum sampling was carried
out at baseline and at the end of the study on the same
date as the clinical evaluation. Fasting blood samples
were immediately centrifuged and stored at -80 °C and
were removed before analysis, which was carried out on
all intervention group samples simultaneously. In the
axSpA control group, blood was withdrawn at each visit,
and the samples were treated as above. CRP was mea-
sured with the immuno-turbidimetric test using a bio-
chemical analyser (Olympus, model AU 400 Japan). IL-6,
IL-17, TNF-α (RayBiotech, Inc., Norcross GA, USA) and
calprotectin (Bühlmann Laboratories AG, Schőnenbuch,
Switzerland) were analysed using a commercially avail-
able enzyme-linked immunosorbent assay (ELISA) ac-
cording to the manufacturer`s protocols. All of the
assays were run in duplicate. The inter-assay and intra-
assay reliability of the IL-6 and IL-17 and TNF-α assays
was <12% and <10%, respectively, and the inter-assay
and intra-assay reliability of calprotectin was 5.8% and
4.3%, respectively. Absorbance was detected using the
Sunrise ELISA reader (Tecan Group Ltd., Salzburg,
Austria) with 450 nm as the primary wavelength. The
sensitivity for IL-6, IL-17, TNF-α and calprotectin was
determined to be 3 pg/mL, 80 pg/mL, 30 pg/mLl and
0.4 μg/mL, respectively.
Statistical analysis
The data are expressed as the means ± standard deviations.
Qualitative variables were tested using the chi-squared or
Fisher’s exact test. Biomarker data were evaluated using
the Friedman test. The variables at baseline and at the end
of the exercise programme were analysed using the non-
parametric Wilcoxon paired test. The differences between
groups were analysed using the non-parametric unpaired
test and the Mann-Whitney U test. Multiple comparisons
were corrected using Monte Carlo exact significance test-
ing. Ordinary least squares (OLS) regression models were
used for predictive analysis. The Spearman correlation
coefficient was used for correlation analysis. P values less
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than 0.05 were considered statistically significant. The
SPSS (version 22) and GraphPad Prism 7 programmes
were used for all analyses.
Results
Clinical characteristics of the cohort
A total of 40 patients with nr-axSpA (n = 18) or AS (n = 22)
completed the exercise and educational programme. Six
patients were excluded for the following reasons: current
inflammatory bowel disease (IBD) in the nr-axSpA group,
exacerbation of peripheral arthritis requiring a change in
long-term therapy (AS group), and four patients who
missed two or more consecutive sessions were also ex-
cluded (nr-axSpA group). At baseline, spondyloarthritic
signs (HLA B27 positivity, extraarticular manifestation,
hip involvement) and treatment were represented equally
in both groups, and there was no significant difference in
age, body mass index (BMI) or smoking history. Patients
characterised as nr-axSpA, however, had significantly
shorter disease duration since the occurrence of first
symptoms and diagnosis (7.10 ± 2.19 versus 12.27 ± 1.42,
p <0.001 and 1.81 ± 0.52 versus 5.84 ± 1.17, respectively,
all p <0.05) and a trend of female predominance was ob-
served (Table 1). During the exercise therapy, there were
no significant differences in BMI, peripheral arthritis or
the need to change long-term medication in either group.
Similarly, the rate of exacerbation of the extraarticular
manifestation was equal in the nr-axSpA and AS groups,
and no patients developed clinical signs of colitis during
the exercise therapy.
Patients in the control axSpA group used sulfasalazine
more often than those in the intervention axSpA group
(44.8% vs. 10.0%, p < 0.05), and more patients with AS in
the intervention group had more frequent history of per-
ipheral arthritis, but the exacerbation of peripheral arth-
ritis was not different from the control group during the
study (45.5% and 4.5% vs. 7.2% and 0%, p < 0.05 and not
significant (ns), respectively). None of the patients from
the control group had any clinical signs of colitis at
baseline or after 6 months (data not shown). There were
no significant differences in any other clinical parame-
ters between the two groups (Additional file 1).
The intensive exercise intervention improved disease
activity
In all of the patients with axSpA who were undergoing
exercise therapy, the ASDAS-CRP score significantly de-
creased after 6 months of exercise (from 2.10 ± 0.12 to
1.84 ± 0.11, p < 0.01). Similarly, the BASMI values were
also significantly lower at the end of the training
programme compared to baseline (from 1.28 ± 0.14 to
0.66 ± 0.84, p < 0.0001) (Table 2). Additionally, there was
a trend of a decline in the BASDAI (p = 0.06), but not in
the BASFI, after 6 months of training (Table 2). The
ASDAS-CRP score consists of four self-assessment ques-
tions, while the BASDAI score only reflects the patients’
outcome reports. In further analyses, we focused on
changes in patients’ reports. For the ASDAS-CRP score,
the following assessments decreased significantly: back
pain (from 4.10 ± 0.34 to 2.97 ± 0.42, p < 0.001) and
Table 1 Demographic and clinical characteristics of patients with axSpA participating in exercise therapy
All (n = 40) AS (n = 22) nr-axSpA (n = 18) P value
Age, years 36.78 ± 1.09 36.91 ± 1.16 36.61 ± 2.03 ns
Gender (% female) 32.5 18.2 50.0 0.05
BMI at baseline 25.25 ± 0.44 25.51 ± 0.76 25.02 ± 0.50 ns
Disease duration since first symptoms (years) 9.94 ± 1.31 12.27 ± 1.42 7.10 ± 2.19 ˂0.001
Disease duration since diagnosis (years) 4.03 ± 0.75 5.84 ± 1.17 1.81 ± 0.52 ˂0.01
HLA-B27 positivity (%) 90.0 90.9 88.8 ns
History of uveitis/exacerbation (%)a 35.0/7.5 27.7/9.1 44.4/5.5 ns
History of peripheral arthritis/exacerbation (%)a 42.5/2.5 45.5/4.5 38.9/0 ns
Hip involvement (%) 17.5% 22.7% 11.1% ns
Therapy - NSA (daily use/on demand) (%) 100 (27.5/72.5) 100 (18.2/81.8) 100 (38.9/61.1) ns
NSA changes during exercise therapy/changes to daily use (%) 7.5/2.5 0/0 16.7/5.5 ns
Therapy - sulfasalazin (%) 10.0 4.5 16.6 ns
Therapy – biological agents (%)b 5.0 9.0 0 ns
Smokers ever/current 25.0/20.0 31.8/27.3 22.2/16.7 ns
aExacerbations of uveitis/arthritis occurred during exercise intervention. No extraarticular signs other than uveitis were manifested. bOnly tumour necrosis factor
alpha inhibitors (TNFi) were used in long-term therapy for high disease activity. Statistical analysis: p value was calculated for comparison between the ankylosing
spondylitis (AS) and the axial non-radiographic spondyloarthritis (nr-axSpA) group using either the Mann-Whitney test or chi-squared/Fisher´s exact test. Data are
characterised as mean ± standard deviation unless stated otherwise. axSpA axial spondyloarthritis, BMI body mass index, NSA non-steroidal antirheumatic drugs,
ns not significant
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patients global (from 3.70 ± 0.36 to 2.50 ± 0.42, p < 0.05).
Only the responses to the first two BASDAI questions im-
proved in patients with axSpA after the exercise interven-
tion (from 37.90 ± 3.50 and 35.70 ± 4.21 to 28.10 ± 3.35 and
25.80 ± 3.15, respectively, p < 0.05 for both comparisons).
The measures of disease activity and severity (ASDAS-
CRP, BASDAI, BASFI and BASMI) did not differ between
groups at baseline or after 6 months of intervention. When
all of the patients from the intervention cohort were di-
vided into non radiographic and radiographic subgroups,
the ASDAS-CRP decreased significantly in the nr-axSpA
subgroup (from 2.01 ± 0.19 to 1.73 ± 0.16, p < 0.05) and
non-significantly in the AS subgroup (from 2.17 ± 0.16 to
1.93 ± 0.15, p = 0.06). The BASMI score decreased after
the intervention in both the nr-axSpA and AS subgroups
(from 1.09 ± 0.12 to 0.47 ± 0.08 and from 1.43 ± 0.24 to
0.82 ± 0.23, respectively, p < 0.0001 for both comparisons)
(Table 2). There were no significant differences between
the two subgroups in the changes in ASDAS-CRP,
BASDAI or BASMI over the exercise training (data not
shown).
In the whole control group of patients with axSpA and
both the nr-axSpA and AS subgroups without physical
intervention, there were no significant changes in the
ASDAS-CRP, BASDAI or BASFI scores between the two
6-month visits. The criterion “no change of therapy” was
required to be included in this group, and this group
served as a control group with stable disease. When we
compared all three scores at visit 2 to the values of the
BASDAI, BASFI and ASDAS-CRP of axSpA after physical
intervention, no significant differences were found (see
Additional file 1). However, when we looked for the
ΔASDAS-CRP and ΔBASDAI, we found a significant
decrease in both parameters in the axSpA exercise group
(-0.26 and -0.49, respectively) compared to axSpA with no
intervention (-0.13 and 0.12, respectively), both p < 0.05
(Table 3).
Calprotectin levels significantly decreased after exercise
therapy in patients with axSpA
Overall, in the axSpA group, there was a significant dif-
ference (p < 0.001, Friedman test) in all biomarkers (CRP,
IL-6, IL-17, TNF-α and calprotectin) at baseline and after
6 months of exercise therapy. However, of the biomarkers,
only calprotectin significantly decreased in patients with
axSpA during the study (from 2408.00 ± 183.30 to
1800.00 ± 101.90 μg/mL, p < 0.001) (Table 2).
There was a significant difference in CRP levels between
the nr-axSpA and AS subgroups at baseline (2.10 ± 0.48
and 6.76 ± 1.45 mg/l, p < 0.001) and after the intervention
(2.16 ± 0.56 and 5.24 ± 1.37 mg/l, p < 0.05), but the other
biomarkers were comparable between both subgroups.
On the other hand, CRP remained unchanged throughout
the study, and only calprotectin significantly decreased
after exercise therapy in both patients with nr-axSpA
(from 2379.0 ± 243.20 to 1779.0 ± 138.3 μg/mL, p < 0.01)
and in pPatients with AS (from 2430.0 ± 269.7 to 1816.0 ±
148.2 μg/mL, p < 0.01) (Table 2).
To exclude variation in calprotectin levels over time, an
analysis of calprotectin levels in the control axSpA group
with no intervention was performed.
Baseline calprotectin levels in the control axSpA
(2749.0 ± 225.8), nr-axSpA (2514.0 ± 303.1) and AS
(3001.0 ± 334.8) groups were similar to the intervention
group and remained unchanged after 6 months in all
axSpA (2579.0 ± 267.9), nr-axSpA (2324.0 ± 381.8) and
AS (2852.0 ± 375.2) groups (data not shown). When the
calprotectin levels at visit 2 in the control axSpA group
were compared to the calprotectin levels in the axSpA
group after the intervention (see previous), the
Table 2 Clinical parameters and biomarker levels of axSpA at baseline and after 6 months of exercise therapy
All axSpA nr-axSpA AS
(n = 40) (n = 18) (n = 22)
Baseline 6 months P value Baseline 6 months P value Baseline 6 months P value
ASDAS-CRP 2.10 ± 0.12 1.84 ± 0.11 <0.01 2.01 ± 0.19 1.73 ± 0.16 <0.05 2.17 ± 0.16 1.93 ± 0.15 ns
BASDAI 2.78 ± 0.31 2.30 ± 0.25 ns 2.98 ± 0.28 2.27 ± 0.41 ns 2.63 ± 0.35 2.31 ± 0.32 ns
BASFI 1.06 ± 0.16 1.01 ± 0.14 ns 1.23 ± 0.28 1.73 ± 0.16 ns 0.92 ± 0.17 0.93 ± 0.18 ns
BASMI 1.28 ± 0.14 0.66 ± 0.84 <0.0001 1.09 ± 0.12 0.47 ± 0.08 <0.0001 1.43 ± 0.24 0.82 ± 0.23 <0.0001
CRP (mg/l) 4.67 ± 0.89 3.86 ± 0.82 ns 2.10 ± 0.48 2.16 ± 0.56 ns 6.76 ± 1.45 5.24 ± 1.37 ns
IL-6 (pg/ml) 10.31 ± 3.93 10.07 ± 4.60 ns 14.78 ± 8.35 15.40 ± 9.79 ns 6.48 ± 1.46 5.51 ± 1.63 ns
IL-17 (pg/ml) 323.50 ± 57.06 401.50 ± 75.87 ns 349.20 ± 82.55 285.30 ± 72.73 ns 301.80 ± 80.57 499.30 ± 123.10 ns
TNF-α (pg/ml) 65.22 ± 12.30 56.89 ± 10.61 ns 55.87 ± 10.49 45.03 ± 6.76 ns 72.49 ± 20.45 62.12 ± 18.06 ns
Calprotectin (ng/ml) 2408.0 ± 183.30 1800.0 ± 101.90 <0.001 2379.0 ± 243.20 1779.0 ± 138.30 <0.01 2430.0 ± 269.70 1816.0 ± 148.20 <0.01
The statistical significance was determined as a p value < 0.05; the paired non parametric test (Wilcoxon) was used for analysis of baseline versus 6 month data for
each group. All data are characterised as mean ± standard deviation. axSpA axial spondyloarthritis, nr-axSpA non-radiographic axial spondyloarthritis, AS ankylosing
spondylitis, ASDAS-CRP AS disease activity score, CRP C-reactive protein, BASDAI Bath AS disease activity index, BASFI Bath AS functional index, BASMI Bath AS
metrology index, IL interleukin, TNF tumour necrosis factor, ns not significant
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Table 3 Comparison of the changes in disease activity scores and biomarkers levels within 6 months in the axSpA groups with and without exercise intervention
All axSpA nr-axSpA AS
Exercise group (n = 40) Without exercise (n = 29) P value Exercise group (n = 18) Without exercise (n = 15) P value Exercise group (n = 22) Without exercise (n = 14) P value
Δ ASDAS-CRP -0.26 (0.58) -0.13 (0.77) <0.05 -0.29 (0.44) 0.03 (0.84) ns -0.24 (0.68) -0.13 (0.72) ns
Δ BASDAI -0.49 (1.40) 0.12 (1.40) <0.05 -0.70 (1.48) 0.42 (1.22) ns -0.32 (1.34) 0.12 (1.22) ns
Δ CRP -0.81 (4.67) -0.33 (9.70) ns 0.06 (1.94) 1.94 (12.20) ns -1.52 (6.02) -2.76 (5.49) ns
Δ Calprotectin -604.56 (1042.80) -149.28 (1255.70) <0.05 -599.42 (824.00) -190.33 (1180.60) ns -608.68 (1211.20) -149.28 (1255.70) ns
Statistical analysis: the comparison of the mean of changes in all parameters was performed using the non-parametric Mann-Whitney U test. The multiple comparisons were corrected using Monte Carlo exact significance
testing. All data are characterised as mean and (standard deviation). axSpA axial spondyloarthritis, nr-axSpA non-radiographic axial spondyloarthritis, AS ankylosing spondylitis, ASDAS-CRP AS disease activity score,













calprotectin levels were lower in all intervention groups
(axSpA, nr-axSpA and AS, p < 0.05, ns and p < 0.05,
respectively). The changes in calprotectin levels were
significantly and consistently lower in the axSpA exer-
cise group than the axSpA control (mean -604.56 vs.
mean -149.28, p < 0.05), see Table 3.
Next, we studied whether improvements in disease ac-
tivity and severity measures (ΔASDAS-CRP, ΔBASDAI,
ΔBASFI and ΔCRP) were associated with changes in
calprotectin levels over time. Using linear regression ana-
lysis, we found a positive association between changes in
CRP and calprotectin over 6 months. Change in CRP of
one unit resulted in an increase in calprotectin of 68 units
(regression coefficient 67.99, p < 0.01) (Additional file 2).
This effect was found in all groups independent of
exercise intervention or subgroup characterisation.
Moreover, in all patients with axSpA irrespective of
exercise therapy, changes in calprotectin positively cor-
related with the changes in CRP (ρ = 0.360, p < 0.01)
and ASDAS-CRP improvement (ρ = 0.285, p < 0.05)
(data not shown).
The other biomarkers modestly reflected changes in
scores for disease activity and mobility after exercise
therapy
In all axSpA groups and in both the nr-axSpA and AS
subgroups, we found positive correlation between
ΔASDAS-CRP and ΔCRP (Table 4). Of the other cyto-
kines, only ΔTNF-α positively reflected improvement in
the clinical variables of ASDAS-CRP and BASMI, particu-
larly in the nr-axSpA group (Table 4). This finding was
supported by the linear regression model, in which only
the effect of ΔTNF-α on the ΔASDAS-CRP and ΔBASMI
was demonstrated in the nr-axSpA (regression coefficient
0.010 and 0.004, respectively, all p < 0.05, data not shown).
On the other hand, there were no relationships between
the selected biomarkers and ΔBASDAI (data not shown).
Discussion
This study demonstrates for the first time the clinical ef-
fectiveness of intensive exercise therapy for both radio-
graphic and non-radiographic forms of axSpA. Although
the outcomes may be affected by several limitations, we
suggest that there was a positive effect on mobility and
clinical activity. In addition, it appears that the reduction
in serum calprotectin might be related to the improved
clinical outcome in patients with axSpA.
The recent recommendations of rehabilitation for pa-
tients with axSpA suggest that complex physical activ-
ities may be used to maintain good clinical status [7].
The general endocrine, immune and metabolic changes
that occur during physical activities might, however, be
stressful, and the effects of exercise on patients with
early stages of axSpA have not yet been examined. In
this study, during the exercise intervention, disease ac-
tivity, as measured by the ASDAS-CRP and BASDAI,
significantly improved over time in subgroups of patients
with both radiographic and non-radiographic axSpA,
which is in agreement with previous studies that have
demonstrated improved disease activity after exercise in
patients with AS [6, 23, 29–31]. Moreover, there was no
difference in extraarticular or articular exacerbations in
either axSpA subgroup, and our clinical data may sup-
port the efficacy and safety of physical therapy not only
in patients with AS but also in patients with nr-axSpA.
The first limitation of this study is the relatively small
number of patients in each subgroup and the inclusion
of patients with stable disease only. However, the small
number reflects the real situation that is present in daily
clinical practice and the need to adjust the exercise
programme for patients with unstable disease as needed.
A second limitation might be the occupational history -
most of the patients with axSpA who participated in this
study were working in white-collar professions. Recently,
Ramiro et al. demonstrated greater radiographic progres-
sion in “blue-collar” workers within 2 years, and this
occupational feature could amplify the effect of ASDAS-
CRP on disease progression [32]. In light of this finding,
the evaluation of the safety and efficacy of physical ther-
apy in blue-collar workers with axSpA or those who per-
form additional physical activities such as sport, requires
larger future studies. The next limitation may be the ab-
sence of imaging of the inflammatory signs in the SIJ
prior to and after exercise therapy. Recent data from the
DESIR cohort suggest a relationship between inflamma-
tion of the SIJ as detected on MRI and the ASDAS score
in male patients [33]. Thus, it can be suggested that
improvement in clinical disease activity after exercise
therapy can be associated with the amelioration of
inflammatory lesions in the SIJ in patients with axSpA.
Further studies should be performed to elucidate this
hypothesis.
After physical therapy, mobility was improved in both
in patients with nr-axSpA and those with AS. However,
our axSpA control group was selected retrospectively,
and the BASMI data were excluded from the analysis;
thus, the change in BASMI cannot be compared. In pa-
tients with AS, the efficacy of supervised and home-
based exercise on mobility is well-demonstrated [29–31],
and a positive effect on BASMI after 24 weeks of an
exercise programme has been identified in TNFi-naive
patients with AS [34] and in those on TNFi treatment
[6, 35]. Our study demonstrated for the first time the
same benefit of exercise therapy on spinal mobility in
patients with nr-axSpA and patients with AS. Although
mobility scores in patients with AS are generally worse
than in patients with nr-axSpA [10, 36, 37], given that
10–12% of patients with nr-axSpA progress to develop
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Table 4 Correlations between the clinical variables and laboratory markers in axSpA with exercise therapy
Δ BASMI Δ ASDAS-CRP CRP baseline IL-6 baseline IL-17 baseline TNF-α baseline Δ CRP Δ IL-6 Δ IL-17 Δ TNF-α
Δ BASMI ρ 1 0.271 -0.017 0.236 -0.027 -0.311 0.003 -0.058 -0.049 0.417
All (n = 40) ρ . ns ns ns ns 0.09 ns ns ns p < 0.05
Δ ASDAS-CRP ρ 0.271 1 -0.231 0.391 -0.131 -0.02 0.406 -0.205 0.035 0.377
All (n = 40) ρ ns . ns p < 0.05 ns ns p < 0.001 ns ns p < 0.05
Δ BASMI ρ 1 0.774 -0.596 0.441 -0.230 -0.477 -0.098 -0.213 0.010 0.563
nr-axSpA (n = 18) ρ . p < 0.001 p < 0.01 ns ns ns ns ns ns p < 0.05
Δ ASDAS-CRP ρ 0.774 1 -0.187 0.388 0.028 -0.351 0.437 -0.249 -0.074 0.636
nr-axSpA (n = 18) ρ p < 0.001 . ns ns ns ns p < 0.05 ns ns p < 0.05
Δ BASMI ρ 1 0.007 0.233 0.099 0.217 -0.143 0.123 0.158 -0.110 0.273
AS (n = 22) ρ . ns ns ns ns ns ns ns ns ns
Δ ASDAS-CRP ρ 0.007 1 -0.328 0.356 -0.266 0.102 0.395 -0.147 0.154 0.186
AS (n = 22) ρ ns . ns ns ns ns p < 0.05 ns ns ns
Statistical analysis: correlation analyses were performed by Spearman correlation (ρ). Statistical significance was determined as p < 0.05. axSpA axial spondyloarthritis, nr-axSpA non-radiographic axial spondyloarthritis,













the form of the disease that is radiographically evident
[10, 38], it seems appropriate to maintain mobility in the
best form possible. In our group, the BASMI scores were
similar in both groups at baseline and after exercise
therapy - this distinction could be confirmed by a lower
BASMI value in patients with AS (1.46 at baseline)
compared to registries (2.84 and 2.0) [10, 36] and was
probably due to the characterisation of patients with
AS who were motivated by the training programme.
However, there was no follow up after the end of the
exercise programme, and thus, we were unable to
demonstrate any long-term positive effects on the
BASMI in the nr-axSpA or AS cohorts. Therefore,
studies with longer follow-up periods are required in
further research.
Increased serum calprotectin has been demonstrated in
patients with other immune-mediated diseases, such as
rheumatoid arthritis (RA) or psoriatic arthritis [39, 40],
and in patients with AS [17, 41, 42] and nr-axSpA [41].
Serum calprotectin in patients with AS appears not to
be influenced by medications such as NSAIDs or
sulphasalazine [41, 43] and tends to be elevated in
patients with AS with active peripheral arthritis [42].
In our study, baseline serum calprotectin was similar
in patients with AS who were or were not on the exercise
programme, although patients with AS who were not
receivingexercise therapy had a more frequent history of
peripheral arthritis.
To the best of our knowledge, we are the first to show
a significant decrease in serum calprotectin after inten-
sive physiotherapy in both nr-axSpA and patients with
AS. As we have not studied the effect of this exercise
programme on serum calprotectin in healthy individuals,
we cannot be sure if this is a disease-specific effect or if
the same might also occur in healthy subjects. Although
skeletal muscles express calprotectin mRNA after con-
tractions [44] and calprotectin plasma levels increase im-
mediately and one hour after aerobic exercise in healthy
individuals [45], there is no long-term effect of muscle
contraction on systemic calprotectin. Kanda et al. per-
formed a study in nine healthy volunteers who performed
one-leg calf-raise exercises that included repetitive muscle
contractions and found no significant differences in
plasma or urine levels of IL-6, TNF-α and calprotectin
immediately after and 96 hours after the exercise [46].
Similarly, Acar et al. recently found only a slight decrease
in calprotectin levels in healthy subjects 8 weeks after they
completed an exercise programme [47]. In agreement with
our study, in patients with RA, the calprotectin levels
decreased significantly and reflected improved disease
activity and a decline in CRP [47].
In our study, the decrease in serum calprotectin levels
was evident in both axSpA subgroups compared to con-
trol subjects with axSpA who underwent no exercise
therapy. Interestingly, the synergistic effect of the decline
in serum calprotectin and clinical improvement was found
in two pharmacological studies in patients with AS, using
TNFi (infliximab) [48] and anti-IL-17 (secukinumab) [49]
treatments. However, in our study, regression analysis
showed only a slight influence of exercise on serum cal-
protectin in patients with axSpA. This finding might be
due to the small sample size. The regression analysis, on
the other hand, supports the relationships between serum
CRP and calprotectin, and those between ASDAS-CRP
improvement and changes in calprotectin. Out of many
biomarkers, serum calprotectin might represent a valuable
tool for the assessment of disease activity improvement in
patients with axSpA. In agreement with Turina et al. [48],
our data also suggest that serum calprotectin may be a
useful biomarker that reflects clinical improvement even
in CRP-negative patients.
Calprotectin likely plays a role in axSpA pathogenesis
and in the disease course. De Rycke et al. demonstrated
10-fold higher calprotectin in inflamed synovium than in
serum [16]. Furthermore, the number of synovial mono-
cytes and granulocytes that release calprotectin rapidly
decreases after TNFi treatment in patients with periph-
eral SpA [50]. Recent data from the GESPIC cohort indi-
cate that elevated serum calprotectin is an independent
predictor of disease progression and syndesmophyte
formation [51]. The precise immune mechanisms that
occur in the inflamed joints during exercise are still un-
clear, but pharmacological studies suggest that decreased
calprotectin serum levels might reflect local inflamma-
tion and possibly new bone formation [48–50]. However,
larger studies based on registries and long-term observa-
tions are needed to evaluate the effect of physiotherapy
on calprotectin and axSpA outcomes.
A possible limitation of our study is the absence of faecal
calprotectin analysis. Faecal calprotectin has been shown
to be elevated in patients with AS and SpA [41, 52], espe-
cially in patients with intestinal inflammatory changes [41]
and in NSAID users [52]. Only 10% of patients with SpA
develop IBD during the disease course [53], but 25–69% of
patients without clinical IBD symptoms may have micro-
scopic intestinal inflammation [43]. In our study, one pa-
tient was excluded due to a diagnosis of IBD, but none of
the other participants underwent ileocolonoscopy because
of a lack of clinical symptoms. Although the increased
CRP and serum calprotectin appear to be predictive
markers for intestinal involvement in SpA [41] and faecal
calprotectin is a well-known marker of IBD activity [54],
there is no correlation between serum and faecal calpro-
tectin [41, 55]. A beneficial effect of mild exercise on the
course of IBD has been suggested [56], but the relationship
between intestinal inflammation and axSpA disease activ-
ity and progression in respect to physical activity requires
further research.
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Finally, in the evaluation of biomarkers after physical
activity, we should bear in mind that exercise is a com-
plex process that may lead to the release of mediators
that influence metabolic, immune and neuroendocrine
pathways. In relation to strenuous exercise, cytokines
such as IL-6, IL-1 receptor antagonist, TNF-α and others
are released over time [57] and regulate hormone,
adaptive and innate immune cell activity. In the
present study, interestingly, the changes in TNF-α
correlated positively with the improvement in
ASDAS-CRP and with the improvement in the mobil-
ity score but only in the nr-axSpA subgroup. There
were no significant differences in calprotectin serum
levels between patients with AS and those with nr-
axSpA. We suggest that patients with axSpA who are
in the early phase of the disease might respond to ex-
ercise differently from those with long-term disease
duration and with different states of inflammation. It
is well-known that both patients with nr-axSpA and
those with AS respond positively to TNFi treatment
[58]. Although the serum levels of TNF-α may not
clearly reflect AS disease activity [59], it can be spec-
ulated that a decrease in TNF-α levels might serve as
a biomarker of milder disease activity. In our study
the levels of IL-17 increased, albeit not significantly,
in the AS group. In healthy male subjects, physical
activity such as high and mild-to-moderate training
have not been shown to influence serum IL-17a [60],
but another study in duathlon athletes suggests a
potential role of the IL-17 axis in muscle damage
after prolonged training [61]. On the other hand,
women with multiple sclerosis were found to have
lower levels of systemic IL-17 and a lower inflamma-
tory status after an 8-week exercise programme [62].
The pivotal role of the IL-17 axis in axSpA pathogen-
esis has been suggested, and inhibition of IL-17 has
recently been demonstrated to be safe and effective
for AS treatment [49, 63]. In light of this, the variation in
serum IL-17 after exercise therapy in the nr-axSpA
and the AS group requires confirmation in further
studies.
Conclusion
In conclusion, this is the first study to show that ex-
ercise therapy is beneficial for both radiographic and
non-radiographic subgroups of axSpA. In addition to
better mobility, disease activity improved after an
intensive exercise programme. This suggests that
exercise should be an essential aspect of the axSpA
treatment strategy, particularly in the early phases of
the disease. In addition, a decrease in serum calpro-
tectin levels reflected improvement in disease activity
in both axSpA subgroups. Larger studies are needed
to confirm our results.
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